Objective: Therapy for hepatocellular carcinoma (HCC) is a major challenge, and targeted
therapies provide only a modest benefit in terms of overall survival. Treatment with …

Novel systemic treatments for hepatocellular carcinoma (HCC) are strongly needed.
Immunotherapy is a promising strategy that can induce specific antitumor immune …

Novel treatment modalities are required urgently in patients with hepatocellular carcinoma
(HCC). A vaccine that induces cytotoxic T lymphocytes (CTLs) is an ideal strategy for cancer …

Hepatocellular carcinoma (HCC), one of the most common and lethal tumors worldwide, is
usually not diagnosed until the disease is advanced, which results in ineffective intervention …

Objective Patients with increased PD-L1+ host cells in tumours are more potent to benefit
from antiprogrammed death-1/programmed death ligand-1 (PD-L1) treatment, but the …

A predictive biomarker of immune checkpoint inhibitor (ICI)-based treatments in
hepatocellular carcinoma (HCC) has not been clearly demonstrated. In this study, we …

Immunotherapy for cancer cells induced by interfering with PD-1/PD-L1 engagement via
check-point blockades was initiated by tumour-specific PD-1+ CD8+ cytotoxic T lymphocytes …

Tumor expression of immune co-inhibitory ligands, such as PD-L1 and Galectin-9, have
potential prognostic value in Hepatocellular Carcinoma (HCC). Circulating levels of these …

Background: Anti-programmed cell death-1 (anti-PD1) treatment has shown promising
antitumor efficacy in patients with advanced hepatocellular carcinoma (HCC). This study …

Conclusions The poor response of liver cancers to αPD‐L1 therapy is largely attributable to
a unique hepatic immunotolerant microenvironment, independent of tumor origins or types …